&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-05-06, 19:00

Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-12, 17:10

Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
Elliot Sizer

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-05-06, 16:00

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
Bradley Crotty

Popular Posts